Ubiquigent enters agreement with Astellas subsidiary, Nanna Therapeutics

FHS
March 11, 2024
12:55 pm

Agreement leverages Ubiquigent’s DUB-focused drug discovery platform to support the development of novel therapeutic candidates for multiple disease targets selected by Nanna Therapeutics.

FDA’s Peter Marks overrode reviewers’ call to reject Sarepta’s new Duchenne gene therapy

Peter Marks, the senior FDA official who oversees the regulation of gene therapies, overrode agency reviewers’ decision to reject Sarepta Therapeutics’ Duchenne muscular dystrophy gene

June 24, 2023

Dementia Tied to Physical Inactivity; Migraine in the ED; Human Brain Project Ends

At least one in 15 dementia cases may be attributable to physical inactivity, a meta-analysis suggested. (Alzheimer’s & Dementia) Intermittent fasting recovered sleep and activity

August 23, 2023

Blood tests for cancer detection aren’t yet ready for prime time

Multi-cancer early detection tests (MCEDs), sometimes called liquid biopsy tests, are a new method of detecting cancer early. While the concept is promising, these untested

June 11, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.